<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of varicella (chickenpox) infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of varicella (chickenpox) infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of varicella (chickenpox) infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mary A Albrecht, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Mitty, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 02, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Varicella-zoster virus (VZV) is one of eight herpesviruses known to cause human infection and is distributed worldwide. Primary infection with VZV causes varicella (chickenpox) in susceptible hosts. Most healthy children have self-limited infection with primary varicella. However, varicella can cause severe complications such as soft tissue infection, pneumonia, hepatitis, Reye syndrome, and encephalitis. Patients at increased risk of complications include adolescents, adults, pregnant women, and immunocompromised hosts.
        </p>
        <p>
         The treatment of primary varicella infection will be reviewed here. Issues related to the transmission, clinical manifestations, and complications of varicella, as well as the management of pregnant women and neonates, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8284.html" rel="external">
          "Clinical features of varicella-zoster virus infection: Chickenpox"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8331.html" rel="external">
          "Varicella-zoster virus infection in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4969.html" rel="external">
          "Varicella-zoster infection in the newborn"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with varicella typically develop a fever and a vesicular rash that is pruritic. Many patients require supportive care to manage these symptoms. (See
         <a class="local">
          'Supportive care'
         </a>
         below.)
        </p>
        <p>
         The decision to initiate antiviral therapy depends upon the patient’s age, the presence or absence of comorbid conditions, and the patient’s clinical presentation. Although varicella is usually a self-limited disease, if complications develop, they can be life-threatening. (See
         <a class="medical medical_review" href="/z/d/html/8284.html" rel="external">
          "Clinical features of varicella-zoster virus infection: Chickenpox", section on 'Complications of varicella'
         </a>
         .)
        </p>
        <p>
         Our approach to antiviral therapy is as follows (see
         <a class="local">
          'Individuals without complications'
         </a>
         below and
         <a class="local">
          'Individuals with complications'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For healthy children ≤12 years, varicella is typically self-limited and we do not routinely offer antiviral therapy. The management of neonatal varicella is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4969.html" rel="external">
          "Varicella-zoster infection in the newborn"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who present with, or are at high risk for complications (eg, unvaccinated adolescents, adults, pregnant women, immunocompromised hosts), we administer antiviral therapy to reduce the severity of symptoms and/or reduce the risk of complications.
        </p>
        <p>
        </p>
        <p>
         We use oral therapy (eg,
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ) for immunocompetent individuals without evidence of complications. The oral agents are well tolerated and there are few serious side effects associated with their use. For most others, we use intravenous acyclovir rather than oral therapy since the bioavailability of intravenous therapy is better than that of the oral agents and it has been widely used for the treatment of immunocompromised hosts.
        </p>
        <p>
         All patients with varicella should be educated about potential complications, including secondary bacterial infections. (See
         <a class="local">
          'Patient monitoring'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following general measures can be used for the symptomatic management of rash and fever, and can also help reduce the risk of developing certain complications:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antihistamines are helpful for the symptomatic treatment of pruritus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fingernails should be closely cropped to avoid significant excoriation and secondary bacterial infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          Acetaminophen
         </a>
         should be used to treat fever, particularly in children. Nonaspirin nonsteroidal antiinflammatory agents can also be used. However, some providers discourage NSAIDS because of the uncertain association with streptococcal superinfection [
         <a href="#rid1">
          1,2
         </a>
         ]. Salicylates should be
         <strong>
          avoided
         </strong>
         since
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         has been associated with the onset of Reye syndrome in the setting of a viral infection [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6154.html" rel="external">
          "Acute toxic-metabolic encephalopathy in children", section on 'Reye syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H167447725">
         <span class="h1">
          ANTIVIRAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         and its analogues (
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         ) are effective for the treatment of primary varicella in both healthy and immunocompromised hosts [
         <a href="#rid4">
          4-11
         </a>
         ]. Higher doses of acyclovir are used to treat VZV compared with herpes simplex virus (HSV). VZV is less susceptible to acyclovir, and 50 percent inhibition of VZV replication requires about 10-fold higher levels of acyclovir than those typically required for HSV [
         <a href="#rid8">
          8,12
         </a>
         ]. Acyclovir and its analogues are dependent upon renal function for clearance and dose adjustment is needed in moderate to severe renal insufficiency.
        </p>
        <p>
         Oral agents are generally very well tolerated, especially in adults; however, gastrointestinal side effects or headache may occur.
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         is also available in an intravenous form which can cause local reactions (phlebitis) and reversible acute kidney injury. Risk factors for acute kidney injury include dehydration, failure to dose adjust for reduced kidney function, and overly rapid infusion (eg, &lt;1 hour) [
         <a href="#rid13">
          13
         </a>
         ]. In addition, for obese adults, weight-based dosing should be scaled to ideal body weight (IBW) rather than total body weight (TBW) to avoid an increased risk of toxicity (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ).
        </p>
        <p>
         Additional discussions on the use of
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         and its analogues are found in the Lexicomp drug information topics within UpToDate and within individual topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8337.html" rel="external">
          "Valacyclovir: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8338.html" rel="external">
          "Famciclovir: An overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H618615445">
         <span class="h1">
          INDIVIDUALS WITHOUT COMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H167447358">
         <span class="h2">
          Immunocompetent children and adolescents
         </span>
        </p>
        <p class="headingAnchor" id="H13871784">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to antiviral therapy for children and adolescents is consistent with the recommendations of the American Academy of Pediatrics [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         We suggest oral antiviral therapy for immunocompetent children and adolescents who are at increased risk of developing complications from varicella (eg, pneumonia, skin infection) [
         <a href="#rid14">
          14-16
         </a>
         ], since antiviral therapy may theoretically reduce the risk of complications in these patients and is generally well tolerated. These individuals include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unvaccinated adolescents (ie, children ≥13 years of age) since these patients are more likely to have severe disease compared with younger children [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary cases in household contacts since these cases are usually more severe than primary cases [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with a history of chronic cutaneous or pulmonary disorders since secondary bacterial infections may have severe consequences.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children taking intermittent oral or inhaled steroid therapy. The risk is greatest when corticosteroids are administered during the incubation period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals taking chronic salicylates. These individuals are at risk of developing Reye syndrome. (See
         <a class="medical medical_review" href="/z/d/html/6154.html" rel="external">
          "Acute toxic-metabolic encephalopathy in children", section on 'Reye syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Although many providers treat immunocompetent children and adolescents at increased risk of complications, others prefer to avoid antiviral agents given the modest decrease in symptoms in immunocompetent hosts [
         <a href="#rid4">
          4,19
         </a>
         ].
        </p>
        <p>
         We suggest
         <strong>
          not
         </strong>
         administering antiviral therapy for healthy children ≤12 years. Varicella is typically a self-limited disease in this population. Although
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         may modestly reduce the duration and severity of symptoms, these benefits must be weighed against the adverse effects (including rare but potentially serious adverse effects), cost, and potential transmission of infection during the office visit to obtain the prescription.
        </p>
        <p>
         The modest effects of oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         are summarized below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial of 815 healthy children with varicella evaluated the effects of oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         [
         <a href="#rid4">
          4
         </a>
         ]. Individuals received placebo or acyclovir therapy (20 mg/kg PO four times daily), which was started within the first 24 hours after the onset of the rash and continued for five days. Acyclovir-treated children had fewer lesions than the placebo group (mean number 294 versus 347), and no new lesions formed after day three in the acyclovir group, while 20 percent of the control group continued to develop lesions on day six or later. In addition, the acyclovir-treated children developed equivalent antibody responses to those given placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of three studies (including the one described above),
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         significantly reduced the duration of fever by 1.1 days (95% CI -1.3 to -0.9) in healthy children with varicella [
         <a href="#rid19">
          19
         </a>
         ]. However, there were no clinically important differences between acyclovir and placebo with respect to developing varicella-related complications or adverse drug events. Acyclovir did not reduce school absence in the only study that evaluated it [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13871625">
         <span class="h3">
          Timing and regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         If antiviral therapy is initiated (eg, immunocompetent patients at increased risk of developing complications from varicella), treatment should be started within 24 hours after the rash develops, if possible. Clinical trial data found greater benefits when antiviral therapy was initiated within 24 hours of symptoms onset [
         <a href="#rid5">
          5,21
         </a>
         ]. In addition, in immunocompetent hosts, viral replication typically stops by 72 hours after the onset of rash.
        </p>
        <p>
         For patients ≥2 years with normal renal function, we administer oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         as follows [
         <a href="#rid22">
          22,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         – 20 mg/kg per dose (maximal dose 800 mg) four times daily for five days for children 2 to 12 years and for adolescents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          Valacyclovir
         </a>
         – 20 mg/kg per dose (maximal dose 1000 mg) three times daily for five days or longer if lesions have not resolved.
        </p>
        <p>
        </p>
        <p>
         We check baseline renal function in children if there is concern for dehydration. Dose adjustments for individuals with reduced kidney function are found in the Lexicomp drug information topic within UpToDate.
        </p>
        <p>
         There is no consensus regarding the optimal dose of oral therapy for children &lt;2 years old. However, some providers would use oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         at the same doses as those recommended for children ≥2 years old. Acyclovir is preferred to
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         for such patients because the safety and efficacy of valacyclovir have not been established in infants younger than two years of age. The treatment of neonatal varicella infection is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4969.html" rel="external">
          "Varicella-zoster infection in the newborn", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H167447855">
         <span class="h2">
          Immunocompetent adults
         </span>
        </p>
        <p class="headingAnchor" id="H13871796">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest oral antiviral therapy (
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          famciclovir
         </a>
         ) for immunocompetent adults with uncomplicated varicella infection. Although most adults who develop varicella have an uncomplicated course, they are at increased risk of developing pneumonia, which often leads to hospitalization and carries an overall mortality of between 10 and 30 percent [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8284.html" rel="external">
          "Clinical features of varicella-zoster virus infection: Chickenpox", section on 'Pneumonia'
         </a>
         .).
        </p>
        <p>
         We administer antiviral therapy to adults even if they were previously vaccinated. There are no data that describe the natural history of varicella in immunized adults. Thus, we prefer to treat with antiviral therapy given the low risk of toxicity with oral agents and the severe potential complications of varicella in adults.
        </p>
        <p>
         Antiviral therapy can reduce the duration and severity of symptoms in adults, and there is a theoretical benefit of antiviral therapy in reducing complications. As an example, in a randomized trial of 148 healthy adults with varicella, which compared oral
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         (800 mg five times per day) with placebo, acyclovir reduced the time to full crusting of lesions (5.6 versus 7.4 days), the maximum number of lesions (46 percent reduction), the duration of fever, and the severity of symptoms [
         <a href="#rid5">
          5
         </a>
         ]. Although this trial did not describe a reduced risk of complications, it was not designed to assess this outcome.
        </p>
        <p class="headingAnchor" id="H13871802">
         <span class="h3">
          Timing and regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         We initiate treatment if the patient has evidence of ongoing disease (eg, active skin lesions). However, the benefit of antiviral therapy has been best described when treatment was initiated within 24 hours of symptom onset [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         We typically administer oral
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         (1 g three times per day) because it can be given in fewer doses compared with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         and has equivalent activity.
         <a class="drug drug_general" data-topicid="8435" href="/z/d/drug information/8435.html" rel="external">
          Famciclovir
         </a>
         can also be used, but valacyclovir provides higher antiviral drug concentrations compared with famciclovir. If oral acyclovir is used, it should be administered as 800 mg five times per day; a randomized trial in adults supports this regimen [
         <a href="#rid5">
          5
         </a>
         ]. Dose adjustments for reduced kidney function are described in the Lexicomp drug information topics within UpToDate.
        </p>
        <p>
         We treat such patients with uncomplicated varicella for five to seven days. However, the course should be extended if there is delayed crusting of lesions.
        </p>
        <p class="headingAnchor" id="H167447706">
         <span class="h2">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest antiviral therapy for pregnant women who present with varicella since they are at high risk for complications. A detailed discussion of varicella in pregnancy is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8331.html" rel="external">
          "Varicella-zoster virus infection in pregnancy", section on 'Treatment of varicella infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1944532770">
         <span class="h2">
          Immunocompromised hosts
         </span>
        </p>
        <p class="headingAnchor" id="H13871826">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend antiviral therapy for immunocompromised hosts who present with varicella. Immunocompromised hosts include those with an underlying malignancy or HIV infection, as well as those who are receiving high-dose corticosteroid therapy for more than 14 days (eg, ≥20 mg or ≥2 mg/kg body weight [for children who weigh &lt;10 kg] of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or equivalent) or other immunosuppressive therapies [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
         Immunocompromised hosts are at risk for developing disseminated varicella due to impaired cellular immunity. Immunocompromised hosts who develop varicella also experience more frequent severe morbidity and higher mortality rates compared with immunocompetent hosts. As an example, while only 0.1 percent of varicella infections develop in this population, this group accounted for as many as 25 percent of varicella-related deaths in the pre-vaccine era [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8284.html" rel="external">
          "Clinical features of varicella-zoster virus infection: Chickenpox", section on 'Immunosuppressed hosts'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13871820">
         <span class="h3">
          Timing and regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         We initiate treatment if active (ie, non-crusted) varicella lesions are present. Clinical trials that evaluated the use of intravenous (IV)
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         in small numbers of immunocompromised children with varicella found that the risk of visceral dissemination and severe complications were reduced in those who received antiviral therapy [
         <a href="#rid7">
          7,29
         </a>
         ].
        </p>
        <p>
         For most patients, we suggest initial therapy with intravenous
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         . However, the antiviral regimen varies with age, disease severity, and baseline laboratories, as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults –
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         10 mg/kg IV every 8 hours (using ideal body weight [IBW] if obese (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         )).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For adults with mild disease (ie, &lt;50 lesions) and normal baseline laboratories (ie, complete blood count, liver function tests, renal function), initiating therapy with
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         is an option if the patient can be followed closely as an outpatient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children ≥1 year of age and adolescents –
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         1500 mg/m
         <sup>
          2
         </sup>
         per day in three divided doses
         <strong>
          or
         </strong>
         30 mg/kg/day in three divided doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Initiating therapy with
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         (20 mg/kg per dose [maximal dose 1000 mg] three times daily) may be reasonable in selected immunocompromised children considered to be at low risk of developing severe varicella if the patient can be followed closely as an outpatient.
        </p>
        <p>
        </p>
        <p>
         Additional dosing recommendations for individuals with reduced kidney function, as well as children &lt;1 year of age, are provided in the Lexicomp drug information topics within UpToDate and within individual topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'Dose adjustments'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4969.html" rel="external">
          "Varicella-zoster infection in the newborn"
         </a>
         .)
        </p>
        <p>
         The typical duration of treatment is 7 to 10 days. Intravenous therapy is continued until no new lesions are occurring. Patients can then be transitioned to oral therapy until all of the lesions have crusted.
        </p>
        <p class="headingAnchor" id="H252835606">
         <span class="h1">
          INDIVIDUALS WITH COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We administer intravenous (IV) antiviral therapy for individuals who present with varicella-related complications, such as severe hepatitis, pneumonia, and encephalitis (see
         <a class="medical medical_review" href="/z/d/html/8284.html" rel="external">
          "Clinical features of varicella-zoster virus infection: Chickenpox", section on 'Complications of varicella'
         </a>
         ). Retrospective analyses and case reports suggest that
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         treatment improves the clinical outcome in adults and children who develop these complications [
         <a href="#rid30">
          30-36
         </a>
         ].
        </p>
        <p>
         The dose of
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         varies with age, as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults – 10 mg/kg IV every eight hours (using IBW if obese (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         )).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children ≥1 year and adolescents – 1500 mg/m
         <sup>
          2
         </sup>
         per day in three divided doses
         <strong>
          or
         </strong>
         30 mg/kg/day in three divided doses.
        </p>
        <p>
        </p>
        <p>
         The dose of IV
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         for patients with reduced kidney function, as well as children &lt;1 year of age, are provided in the Lexicomp drug information topics within UpToDate and within individual topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'Dose adjustments'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4969.html" rel="external">
          "Varicella-zoster infection in the newborn"
         </a>
         .)
        </p>
        <p>
         Antiviral therapy should be continued for 7 to 10 days. Individuals who have a more rapid response to treatment (eg, significant improvement in symptoms and no new lesions) can be transitioned to oral therapy to complete the treatment course.
        </p>
        <p class="headingAnchor" id="H1944531840">
         <span class="h1">
          PATIENT MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are treated as an outpatient should be instructed to call their providers if they develop signs and symptoms of complicated varicella (eg, cough, severe headache, confusion, nausea, and vomiting) or a secondary bacterial infection (eg, cellulitis).
        </p>
        <p>
         Individuals who require intravenous
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         should have their blood urea nitrogen level and creatinine followed while receiving intravenous treatment. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'Toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19803788">
         <span class="h1">
          INFECTION CONTROL PRECAUTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hospitalized patients with primary varicella should be placed on standard, contact, and airborne precautions to prevent the spread of infection to others. A detailed discussion on infection control precautions for patients with primary varicella is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4047.html" rel="external">
          "Prevention and control of varicella-zoster virus in hospitals", section on 'Isolation precautions for patients with varicella'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3582696063">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110219.html" rel="external">
          "Society guideline links: Varicella-zoster virus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23359159">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15375.html" rel="external">
          "Patient education: Chickenpox (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/3997.html" rel="external">
          "Patient education: Chickenpox prevention and treatment (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with varicella typically develop a fever and a vesicular rash that is pruritic. Many patients require supportive care to manage these symptoms. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For healthy children ≤12 years, varicella is typically self-limited and we suggest
         <strong>
          not
         </strong>
         administering antiviral therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, we suggest antiviral therapy for immunocompetent children and adolescents who are at increased risk of developing complications from varicella (eg, unvaccinated patients ≥13 years old, individuals with chronic cutaneous or pulmonary disorders, those taking chronic salicylates or inhaled steroids) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Immunocompetent children and adolescents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For immunocompetent adults with uncomplicated varicella infection, we suggest oral antiviral therapy in addition to supportive care rather than supportive care alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Antiviral therapy can reduce the severity of symptoms and may decrease the risk of complications. We initiate antiviral therapy, regardless of the individual’s vaccination status. We typically administer oral
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         because it can be given in fewer doses compared with
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         and has equivalent activity. (See
         <a class="local">
          'Immunocompetent adults'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For immunocompromised individuals who present with varicella, we recommend antiviral treatment in addition to supportive care rather than supportive care alone (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). For most patients, we suggest initial therapy with intravenous
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         rather than oral agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Treatment should be administered for 7 to 10 days. (See
         <a class="local">
          'Immunocompromised hosts'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For pregnant women who develop uncomplicated varicella, we suggest oral antiviral therapy rather than supportive care (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The management of pregnant women with varicella is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8331.html" rel="external">
          "Varicella-zoster virus infection in pregnancy", section on 'Treatment of varicella infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who present with complications related to varicella, intravenous
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         should be initiated. Antiviral therapy should be continued for 7 to 10 days. (See
         <a class="local">
          'Individuals with complications'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis 2002; 34:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesko SM, O'Brien KL, Schwartz B, et al. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics 2001; 107:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belay ED, Bresee JS, Holman RC, et al. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 1999; 340:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunkle LM, Arvin AM, Whitley RJ, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991; 325:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace MR, Bowler WA, Murray NB, et al. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feder HM Jr. Treatment of adult chickenpox with oral acyclovir. Arch Intern Med 1990; 150:2061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis 1988; 157:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogilvie MM. Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect 1998; 36 Suppl 1:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunha BA, Baron J. The pharmacokinetic basis of oral valacyclovir treatment of herpes simplex virus (HSV) or varicella zoster virus (VZV) meningitis, meningoencephalitis or encephalitis in adults. J Chemother 2017; 29:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu H, Zhu QR, Wang ZL, et al. [Randomized controlled multi-center trial for treatment of varicella in pediatric patients with hydrochloride valacyclovir]. Zhonghua Er Ke Za Zhi 2008; 46:454.
          </a>
         </li>
         <li class="breakAll">
          Canadian Agency for Drugs and Technologies in Health. Acyclovir versus Valacyclovir for Herpes Virus in Children and Pregnant Women: A Review of the Clinical Evidence and Guidelines. September 5 2014
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biron KK, Elion GB. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother 1980; 18:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drugs for non-HIV viral infections. Treat Guidel Med Lett 2005; 3:23.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Varicella-zoster virus infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca IL 2021. p.831.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kesson AM, Grimwood K, Burgess MA, et al. Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. J Paediatr Child Health 1996; 32:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008; 197 Suppl 2:S94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balfour HH Jr, Rotbart HA, Feldman S, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group. J Pediatr 1992; 120:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klassen TP, Hartling L, Wiebe N, Belseck EM. Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database Syst Rev 2005; :CD002980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balfour HH Jr, Kelly JM, Suarez CS, et al. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 1990; 116:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balfour HH Jr, Edelman CK, Anderson RS, et al. Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance. Pediatr Infect Dis J 2001; 20:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kechagia IA, Kalantzi L, Dokoumetzidis A. Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling. Pediatr Infect Dis J 2015; 34:1342.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Non-HIV antiviral drugs. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.930.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995; 172:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Varicella-related deaths among adults--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller E, Vardien J, Farrington P. Shift in age in chickenpox. Lancet 1993; 341:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill G, Chauvenet AR, Lovato J, McLean TW. Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics 2005; 116:e525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Straus SE, Ostrove JM, Inchauspé G, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study. J Pediatr 1982; 101:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haake DA, Zakowski PC, Haake DL, Bryson YJ. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 1990; 12:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tojimbara T, So SK, Cox KL, et al. Fulminant hepatic failure following varicella-zoster infection in a child. A case report of successful treatment with liver transplantation and perioperative acyclovir. Transplantation 1995; 60:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002; 186 Suppl 1:S91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee S, Ito N, Inagaki T, et al. Fulminant varicella infection complicated with acute respiratory distress syndrome, and disseminated intravascular coagulation in an immunocompetent young adult. Intern Med 2004; 43:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frangides CY, Pneumatikos I. Varicella-zoster virus pneumonia in adults: report of 14 cases and review of the literature. Eur J Intern Med 2004; 15:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roque-Afonso AM, Bralet MP, Ichai P, et al. Chickenpox-associated fulminant hepatitis that led to liver transplantation in a 63-year-old woman. Liver Transpl 2008; 14:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8336 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11797168" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11331694" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10228187" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Reye's syndrome in the United States from 1981 through 1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1944438" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A controlled trial of acyclovir for chickenpox in normal children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1323943" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2222091" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Treatment of adult chickenpox with oral acyclovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2826611" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acyclovir prevents dissemination of varicella in immunocompromised children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9514106" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26239190" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The pharmacokinetic basis of oral valacyclovir treatment of herpes simplex virus (HSV) or varicella zoster virus (VZV) meningitis, meningoencephalitis or encephalitis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19099786" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : [Randomized controlled multi-center trial for treatment of varicella in pediatric patients with hydrochloride valacyclovir].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19099786" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : [Randomized controlled multi-center trial for treatment of varicella in pediatric patients with hydrochloride valacyclovir].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6252836" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : In vitro susceptibility of varicella-zoster virus to acyclovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767977" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Drugs for non-HIV viral infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767977" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Drugs for non-HIV viral infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8827537" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18419417" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Varicella among adults: data from an active surveillance project, 1995-2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1313098" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17046469" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Varicella.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16235308" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Acyclovir for treating varicella in otherwise healthy children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2156984" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acyclovir treatment of varicella in otherwise healthy children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11642624" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26379165" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26379165" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7658062" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The epidemiology of varicella and its complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9162840" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Varicella-related deaths among adults--United States, 1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8093945" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Shift in age in chickenpox.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16199681" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2829675" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6750068" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2237118" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7491682" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Fulminant hepatic failure following varicella-zoster infection in a child. A case report of successful treatment with liver transplantation and perioperative acyclovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12353193" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Varicella-zoster virus: atypical presentations and unusual complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15645661" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Fulminant varicella infection complicated with acute respiratory distress syndrome, and disseminated intravascular coagulation in an immunocompetent young adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522570" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Varicella-zoster virus pneumonia in adults: report of 14 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18756459" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chickenpox-associated fulminant hepatitis that led to liver transplantation in a 63-year-old woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18582201" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
